scholarly journals Treatment of the behavioral variant of frontotemporal dementia: a narrative review

2021 ◽  
Vol 15 (3) ◽  
pp. 331-338
Author(s):  
Leandro Boson Gambogi ◽  
Henrique Cerqueira Guimarães ◽  
Leonardo Cruz de Souza ◽  
Paulo Caramelli
Keyword(s):  
Frontotemporal Dementia ◽  
Neurodegenerative Disorder ◽  
Treatment Options ◽  
Specific Treatment ◽  
Narrative Review ◽  
Disease Modifying Drugs ◽  
Predominant Symptom ◽  
Symptom Profile ◽  
Disease Modifying ◽  
Therapeutic Recommendation

ABSTRACT Frontotemporal dementia (FTD) is a progressive neurodegenerative disorder accompanied by behavioral and personality changes and/or language deterioration. Its behavioral variant (bvFTD) is the main clinical presentation. Objective: This study aims to investigate the treatment alternatives for bvFTD available so far. Methods: We conducted a narrative review of bvFTD treatment options. We used PubMed and Lilacs databases with the terms “frontotemporal dementia” or “behavioral variant frontotemporal dementia” combined with “treatment,” “pharmacological treatment,” or “disease-modifying drugs.” Results: The articles retrieved and selected in the research pointed out that there is no specific treatment approved for bvFTD so far. The current proposals are limited to handle the cardinal behavioral symptoms of the disorder. Disease-modifying drugs are under development and may be promising, especially in the monogenic presentations of FTD. Conclusions: There are numerous approaches to treat the core symptoms of bvFTD, most of them based on low-quality research. To date, there are no drugs with a disease-specific therapeutic recommendation for bvFTD. Treatments are often investigated guided by primary psychiatric disorders with similar symptoms and should be chosen by the predominant symptom profile.

scholarly journals Alzheimer’s Disease: Current and Future Treatments. A Review

2014 ◽  
Vol 2 (2) ◽  
pp. 56-63
Author(s):  
Evelyn Chou
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cholinesterase Inhibitors ◽  
Neurodegenerative Disorder ◽  
Nmda Antagonists ◽  
Disease Modifying Drugs ◽  
Plaque Deposition ◽  
The Future ◽  
Disease Modifying ◽  
Future Treatments

Alzheimer’s disease (AD) is a currently incurable neurodegenerative disorder whose treatment poses a big challenge. Proposed causes of AD include the cholinergic, amyloid and tau hypotheses. Current therapeutic treatments have been aimed at dealing with the neurotransmitter imbalance. These include cholinesterase inhibitors and N-Methyl-D-aspartate (NMDA) antagonists. However, current therapeutics have been unable to halt AD progression. Much research has gone into the development of disease-modifying drugs to interfere with the course of the disease. Approaches include secretase inhibition and immunotherapy aimed at reducing plaque deposition. However, these have not been successful in curing AD as yet. It is believed that the main reason why therapeutics have failed to work is that treatment begins too late in the course of the disease. The future of AD treatment thus appears to lie with prevention rather than cure. In this article, current therapeutics and, from there, the future of AD treatment are discussed.

Promising therapies for the treatment of frontotemporal dementia clinical phenotypes: from symptomatic to disease-modifying drugs

2019 ◽  
Vol 20 (9) ◽  
pp. 1091-1107 ◽  
Author(s):  
Giancarlo Logroscino ◽  
Bruno P. Imbimbo ◽  
Madia Lozupone ◽  
Rodolfo Sardone ◽  
Rosa Capozzo ◽  
...  
Keyword(s):  
Frontotemporal Dementia ◽  
Disease Modifying Drugs ◽  
Clinical Phenotypes ◽  
Disease Modifying

scholarly journals Patient-Derived Induced Pluripotent Stem Cell-Based Models in Parkinson’s Disease for Drug Identification

2020 ◽  
Vol 21 (19) ◽  
pp. 7113
Author(s):  
Georgia Kouroupi ◽  
Nasia Antoniou ◽  
Kanella Prodromidou ◽  
Era Taoufik ◽  
Rebecca Matsas
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Drug Discovery ◽  
Neurodegenerative Disorder ◽  
Induced Pluripotent Stem Cell ◽  
Cellular Systems ◽  
Complex Data ◽  
Disease Modifying Drugs ◽  
Disease Modifying ◽  
Induced Pluripotent

Parkinson’s disease (PD) is a common progressive neurodegenerative disorder characterized by loss of striatal-projecting dopaminergic neurons of the ventral forebrain, resulting in motor and cognitive deficits. Despite extensive efforts in understanding PD pathogenesis, no disease-modifying drugs exist. Recent advances in cell reprogramming technologies have facilitated the generation of patient-derived models for sporadic or familial PD and the identification of early, potentially triggering, pathological phenotypes while they provide amenable systems for drug discovery. Emerging developments highlight the enhanced potential of using more sophisticated cellular systems, including neuronal and glial co-cultures as well as three-dimensional systems that better simulate the human pathophysiology. In combination with high-throughput high-content screening technologies, these approaches open new perspectives for the identification of disease-modifying compounds. In this review, we discuss current advances and the challenges ahead in the use of patient-derived induced pluripotent stem cells for drug discovery in PD. We address new concepts implicating non-neuronal cells in disease pathogenesis and highlight the necessity for functional assays, such as calcium imaging and multi-electrode array recordings, to predict drug efficacy. Finally, we argue that artificial intelligence technologies will be pivotal for analysis of the large and complex data sets obtained, becoming game-changers in the process of drug discovery.

scholarly journals Disease-Modifying Drugs and Family Planning in People with Multiple Sclerosis: A Consensus Narrative Review from the Gulf Region

2020 ◽  
Vol 9 (2) ◽  
pp. 265-280
Author(s):  
Raed Alroughani ◽  
Jihad Inshasi ◽  
Abdullah Al-Asmi ◽  
Jaber Alkhabouri ◽  
Taoufik Alsaadi ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Family Planning ◽  
Narrative Review ◽  
Gulf Region ◽  
Disease Modifying Drugs ◽  
Disease Modifying

Development of disease-modifying drugs for frontotemporal dementia spectrum disorders

2020 ◽  
Vol 16 (4) ◽  
pp. 213-228 ◽  
Author(s):  
Francesco Panza ◽  
Madia Lozupone ◽  
Davide Seripa ◽  
Antonio Daniele ◽  
Mark Watling ◽  
...  
Keyword(s):  
Frontotemporal Dementia ◽  
Disease Modifying Drugs ◽  
Disease Modifying ◽  
Spectrum Disorders

scholarly journals New Avenues for the Treatment of Huntington’s Disease

2021 ◽  
Vol 22 (16) ◽  
pp. 8363
Author(s):  
Amy Kim ◽  
Kathryn Lalonde ◽  
Aaron Truesdell ◽  
Priscilla Gomes Welter ◽  
Patricia S. Brocardo ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Clinical Studies ◽  
Neurodegenerative Disorder ◽  
Genetic Disorder ◽  
Treatment Options ◽  
Genetic Manipulations ◽  
Cag Expansion ◽  
Disease Modifying

Huntington’s disease (HD) is a neurodegenerative disorder caused by a CAG expansion in the HD gene. The disease is characterized by neurodegeneration, particularly in the striatum and cortex. The first symptoms usually appear in mid-life and include cognitive deficits and motor disturbances that progress over time. Despite being a genetic disorder with a known cause, several mechanisms are thought to contribute to neurodegeneration in HD, and numerous pre-clinical and clinical studies have been conducted and are currently underway to test the efficacy of therapeutic approaches targeting some of these mechanisms with varying degrees of success. Although current clinical trials may lead to the identification or refinement of treatments that are likely to improve the quality of life of those living with HD, major efforts continue to be invested at the pre-clinical level, with numerous studies testing novel approaches that show promise as disease-modifying strategies. This review offers a detailed overview of the currently approved treatment options for HD and the clinical trials for this neurodegenerative disorder that are underway and concludes by discussing potential disease-modifying treatments that have shown promise in pre-clinical studies, including increasing neurotropic support, modulating autophagy, epigenetic and genetic manipulations, and the use of nanocarriers and stem cells.

Rapid Diagnosis of Parkinson’s Disease from Sebum using Paper Spray Ionisation Ion Mobility Mass Spectrometry

2020 ◽  
Author(s):  
Depanjan Sarkar ◽  
Drupad Trivedi ◽  
Eleanor Sinclair ◽  
Sze Hway Lim ◽  
Caitlin Walton-Doyle ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Ion Mobility ◽  
Neurodegenerative Disorder ◽  
Treatment Options ◽  
Ion Mobility Mass Spectrometry ◽  
Paper Spray ◽  
Molecular Features ◽  
Validation Set

Parkinson’s disease (PD) is the second most common neurodegenerative disorder for which identification of robust biomarkers to complement clinical PD diagnosis would accelerate treatment options and help to stratify disease progression. Here we demonstrate the use of paper spray ionisation coupled with ion mobility mass spectrometry (PSI IM-MS) to determine diagnostic molecular features of PD in sebum. PSI IM-MS was performed directly from skin swabs, collected from 34 people with PD and 30 matched control subjects as a training set and a further 91 samples from 5 different collection sites as a validation set. PSI IM-MS elucidates ~ 4200 features from each individual and we report two classes of lipids (namely phosphatidylcholine and cardiolipin) that differ significantly in the sebum of people with PD. Putative metabolite annotations are obtained using tandem mass spectrometry experiments combined with accurate mass measurements. Sample preparation and PSI IM-MS analysis and diagnosis can be performed ~5 minutes per sample offering a new route to for rapid and inexpensive confirmatory diagnosis of this disease.

Sign in / Sign up

Export Citation Format

Share Document